Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Gain Therapeutics, Inc.

< Previous 1 2 Next >
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Present at Public Ventures Discovery Day
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate in AI Driven Drug Discovery Summit
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson’s Disease Model
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson’s Disease and Movement Disorders®
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics to Present at the Jefferies Healthcare Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Awarded CHF 2.5 million Innosuisse Grant to Advance Lead Program in GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers AGEN GANX
Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
Gain Therapeutics Reports Full Year 2022 Financial Results and Business Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
Tickers GANX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.